Novo Nordisk Makes FORTUNE's List of '100 Best Companies to Work For'

Second Consecutive Year for Diabetes Care Leader

Jan 21, 2010, 15:49 ET from Novo Nordisk

PRINCETON, N.J., Jan. 21 /PRNewswire-FirstCall/ -- Novo Nordisk, a global healthcare company focusing on diabetes care, has been named to FORTUNE Magazine's list of "100 Best Companies to Work For" 2010.  This is the second consecutive year that Novo Nordisk has been recognized with this prestigious award. Novo Nordisk moved up to 25 from 57 in the overall list and is only one of two pharmaceutical/biotechnology companies so honored.    

"This continued recognition by FORTUNE as one of the '100 Best Companies to Work For' is a reflection of the passion of our employees," said Jerzy Gruhn, president of Novo Nordisk Inc. "Our ambition to defeat diabetes is one that is shared equally throughout Novo Nordisk, from the field to the home office to the lab bench."

To pick the 100 Best Companies, FORTUNE partners with the Great Place to Work Institute® to conduct the most extensive employee survey in corporate America. Most (two-thirds) of a company's score is based on the results of the Institute's Trust Index survey, which is sent to a random sample of employees from each company. This year, 343 companies participated in the survey. FORTUNE's "100 Best Companies to Work For" are historically good performers in the marketplace for not only current and prospective employees, but shareholders as well.

"At Novo Nordisk, we believe strongly in cultivating the talent of our employees and rewarding them for contributing to the success of our business," said Jeff Frazier, Vice President of Human Resources.  "This has enabled us to attract and retain the most-talented people with a passion for advancing the treatment and care of the patients who use our products."

About Novo Nordisk

Novo Nordisk is a healthcare company with an 87-year history of innovation and achievement in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition to diabetes care, Novo Nordisk has a leading position within areas such as hemostasis management, growth hormone therapy, and hormone therapy for women. Novo Nordisk's business is driven by the Triple Bottom Line: a commitment to social responsibility to employees and customers, environmental soundness and economic success. With headquarters in Denmark, Novo Nordisk employs more than 29,000 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For global information, visit; for United States information, visit  

SOURCE Novo Nordisk